ReviewBlood advances2026
Treatment of von Willebrand disease.
Review in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- von Willebrand disease: an illustrated review.Research and practice in thrombosis and haemostasis · 2026Review
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractTreatment for von Willebrand disease (VWD), the most common inherited bleeding disorder, has advanced considerably since its initial description by Erik von Willebrand who first described a family in the Åland Islands with severe bleeding. Infusion of von Willebrand factor (VWF)-containing concentrates continues to serve as the foundation of management, in addition to desmopressin, hormonal therapies, and antifibrinolytic agents such as tranexamic acid. Recent advancements in VWD management are underscored by the publication of evidence-based international guidelines addressing critical aspects such as VWF prophylaxis, the use of anticoagulants and antiplatelet agents for cardiovascular disease, and comprehensive management during surgical as well as obstetric and gynecologic scenarios. This review provides an overview of modern treatment strategies, discusses management in special populations, and explores emerging therapies and future directions for improving VWD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.